Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal - a single institution experience

1. Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983; 52: 1849-55.10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-XSearch in Google Scholar

2. Sobrinho-Simões M, Albores-Saavedra J, Tallini G. Poorly differentiated carcinoma. In: DeLellis RA, Lloyd RV, Heitz U, Eng C, editors, Pathology and genetics. Tumours of endocrine organs. Lyon: World Health Organization, IARC Press, France; 2004. p. 73-6.Search in Google Scholar

3. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007; 31: 1256-64.10.1097/PAS.0b013e3180309e6aSearch in Google Scholar

4. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006; 13: 119-28.10.1177/107327480601300206Search in Google Scholar

5. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol 2010; 23: 1269-78.10.1038/modpathol.2010.117Search in Google Scholar

6. Ito Y, Hirokawa M, Fukushima M, Inoue H, Yabuta T, Uruno T, et al. Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg 2008; 32: 1535-43.10.1007/s00268-007-9406-7Search in Google Scholar

7. Sanders EM Jr, LiVolsi VA, Brierley J, Shin J, Randolph GW. An evidence-based review of poorly differentiated thyroid cancer. World J Surg 2007; 31: 934-45.10.1007/s00268-007-9033-3Search in Google Scholar

8. Auersperg M, Us-Krasovec M, Petric G, Pogacnik A, Besic N. Results of combined modality treatment in poorly-differentiated and anaplastic thyroid carcinoma. Wien Klin Wochenschr 1990; 102: 267-70.Search in Google Scholar

9. Ibrahimpasic T, Ghossein R, Carlson DL, Chernichenko N, Nixon I, Palmer FL, et al. Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986-2009 Memorial Sloan-Kettering Cancer Center experience. Thyroid 2013; 23: 997-1002.10.1089/thy.2012.0403Search in Google Scholar

10. Lai HW, Lee CH, Chen JY, Tseng LM, Yang AH. Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy. J Am Coll Surg 2006; 203: 715-22.10.1016/j.jamcollsurg.2006.07.008Search in Google Scholar

11. Justin EP, Seabold JE, Robinson RA, Walker WP, Gurll NJ, Hawes DR. Insular carcinoma: a distinct thyroid carcinoma with associated iodine-131 localization. J Nucl Med 1991; 32: 1358-63.Search in Google Scholar

12. Besic N, Auersperg M, Dremelj M, Vidergar-Kralj B, Gazic B. Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma. Thyroid 2013; 23: 178-84.10.1089/thy.2012.0194Search in Google Scholar

13. Besic N, Auersperg M, Gazic B, Dremelj M, Zagar I. Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or Hürthle cell thyroid carcinoma: a phase 2 study. Thyroid 2012; 22: 131-7.10.1089/thy.2011.0243Search in Google Scholar

14. Sobin LH, Gospodarowitz MK, Witekind C. Thyroid gland (ICD-O C73). In: Sobin LH, Gospodarowitz MK, Witekind C, editors. TNM classification of malignant tumours. 7th edition. New York: Wiley Blackwell; 2009. p. 58-62.10.1002/9780471420194.tnmc08.pub2Search in Google Scholar

15. Dobrenic M, Huic D, Zuvic M, Grosev D, Petrovic R, Samardzic T. Usefulness of low iodine diet in managing patients with differentiated thyroid cancer - initial results. Radiol Oncol 2011; 45: 189-95.10.2478/v10019-011-0017-4342373722933955Search in Google Scholar

16. Auersperg M, Us-Krasovec M, Pogacnik A, Hocevar M, Novak B, Besic N, et al. Induction chemotherapy in primarily inoperable differentiated thyroid carcinomas. Radiol Oncol 1993; 27: 187-91.Search in Google Scholar

17. Zager V, Cemazar M, Hreljac I, Lah TT, Sersa G, Filipic M. Development of human cell biosensor system for genotoxicity detection based on DNA damage-induced gene expression. Radiol Oncol 2010; 44: 42-51.10.2478/v10019-010-0010-3342366922933890Search in Google Scholar

18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.10.1016/j.ejca.2008.10.02619097774Search in Google Scholar

19. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly-differentiated thyroid cancer. J Clin Endocrinol Metab 2002; 87: 4160-5.10.1210/jc.2001-01115112213865Search in Google Scholar

20. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.10.1089/thy.2009.011019860577Search in Google Scholar

21. Marinko T, Dolenc J, Bilban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiol Oncol 2014; 48: 105-12.10.2478/raon-2013-0040407802824991199Search in Google Scholar

22. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. The European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.10.1530/eje.1.0215816728537Search in Google Scholar

23. Jung TS, Kim TY, Kim KW, Oh YL, Park do J, Cho BY, et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J 2007; 54: 265-74.10.1507/endocrj.K06-166Search in Google Scholar

24. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 2013; 23: 1277-83.10.1089/thy.2013.0057396741523489023Search in Google Scholar

25. Liu M, Shen Y, Ruan M, Li M, Chen L. Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. Thyroid 2014; 24: 1179-83.10.1089/thy.2013.070324684401Search in Google Scholar